Shares of Vital Therapies Inc (NASDAQ:VTL) gapped up prior to trading on Wednesday . The stock had previously closed at $0.30, but opened at $0.31. Vital Therapies shares last traded at $0.30, with a volume of 77051 shares trading hands.
A number of equities analysts recently weighed in on the stock. BidaskClub raised shares of Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 12th. BTIG Research reaffirmed a “hold” rating on shares of Vital Therapies in a research note on Thursday, August 9th. Raymond James lowered shares of Vital Therapies from an “outperform” rating to a “market perform” rating and set a $6.00 target price for the company. in a research note on Wednesday, September 12th. William Blair reaffirmed a “buy” rating on shares of Vital Therapies in a research note on Sunday, August 12th. Finally, Cantor Fitzgerald assumed coverage on shares of Vital Therapies in a research note on Monday, August 20th. They issued an “overweight” rating and a $18.00 target price for the company. Seven research analysts have rated the stock with a hold rating, The stock presently has a consensus rating of “Hold” and an average price target of $12.00.
The company has a market capitalization of $11.67 million, a price-to-earnings ratio of -0.24 and a beta of 4.29.
In other news, Director Muneer A. Satter sold 447,500 shares of the stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $0.36, for a total transaction of $161,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Muneer A. Satter sold 11,382,277 shares of the stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $0.36, for a total transaction of $4,097,619.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,929,271 shares of company stock valued at $4,292,912. Company insiders own 33.90% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Citigroup Inc. boosted its stake in shares of Vital Therapies by 1,093.5% during the 1st quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock worth $108,000 after buying an additional 14,576 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new position in shares of Vital Therapies during the 2nd quarter worth about $139,000. Rhumbline Advisers acquired a new position in shares of Vital Therapies during the 2nd quarter worth about $183,000. Element Capital Management LLC acquired a new position in shares of Vital Therapies during the 1st quarter worth about $209,000. Finally, TD Asset Management Inc. boosted its stake in shares of Vital Therapies by 50.2% during the 2nd quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock worth $249,000 after buying an additional 12,144 shares during the last quarter. Institutional investors own 32.62% of the company’s stock.
About Vital Therapies (NASDAQ:VTL)
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.